Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Replimune price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
No price to sales ratio figures for Replimune
Replimune has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?